Mark is the founder of PHMR and has developed the company into a successful health economics, pricing and market access consultancy working with a range of top 10 pharma companies. He has a vast amount of experience in the health economics, pricing, reimbursement and market access fields. He also possesses decades of experience with major international pharmaceutical companies and previous work in senior economics research positions.

Michael is involved across a range of health economics, outcomes research and market access projects at PHMR and is responsible for ensuring that the research delivered matches the strategic needs of our clients. Michael has extensive experience in the development of health economic models and indirect treatment comparisons, utility measurement and health valuation, strategies for collection and use of real-world data, as well as the development of dossiers to support HTA submission. He also has substantial experience in working with different stakeholders, including through the use of early scientific advice through HTA agencies, to lead the development of integrated evidence plans and allow for access needs to be incorporated from early in product development. Michael has led projects across many different therapeutic areas, with expertise in fields including oncology, GI, neuroscience, rare disease, and cardiovascular disease. Michael has also published his research in peer-reviewed journals and presented work at multiple international conferences. He has led educational initiatives to shape HTA policy which involved delivering symposiums at international conferences and developing publications to support the use of innovative methodologies to demonstrate the value of new immuno-oncology medicines.

Koonal is a health economist with expertise in stated preference methods, the measurement and valuation of health, and the use of social value judgements in HTA decision making. He has written extensively on patient-reported outcomes and HTA policy (focusing on the assessment of cancer and end of life treatments) and has published over 40 peer-reviewed journal articles and book chapters. He has led high-profile projects across a broad range of clinical and methodological areas, with his work on the generation and analysis of utility values used in a large number of HTA submissions. Koonal is a member of the EuroQol Group (an international network of researchers that developed the EQ-5D family of instruments) and currently serves on the Group’s Executive Committee. He is also an Honorary Research Fellow at the University of Sheffield’s School of Health and Related Research.

Matt is a health economist with extensive experience in conducting economic evaluations of new treatments and specialises in long-term modelling, with knowledge of a variety of software and conceptual models. He has contributed to and advised biopharma clients on submissions to a number of HTA agencies. He has also contributed health economic input to the design of numerous randomised controlled trials and analysed and synthesised trial data.

Vlad is a health economist with substantial experience of leading cost-effectiveness and budget impact modelling projects. He has extensive knowledge of statistical methods applicable to economic evaluation through his experience in trial-based economic evaluation and decision-analytic modelling to support HTA submissions. Vlad has expertise in long-term modelling in rare diseases, including therapeutic areas with sparse evidence of long-term costs and benefits of treatment. His other research interests include the application of propensity scores to adjust for confounding in observational studies and the use of indirect comparisons of efficacy of treatments in the absence of head-to-head trials.

Lynsey is the scientific office manager and administrator at PHMR. Her extensive experience in the life sciences and with rapidly growing healthcare consultancies results in a skill set which bridges the gap between business and science. She is passionate about bringing PHMR’s values to life by facilitating and supporting the development of lasting client partnerships; the delivery of quality science with integrity; and the cultivation of a supportive, skill sharing environment. Her drive to optimise organisation and efficiency reinforces the delivery of PHMR’s consistently high standards.

Gintare, Assoc CIPD, keeps HR operations aligned to the company values and brings the skills, knowledge and energy required to ensure PHMR is a great place to work.

India joined PHMR having successfully completed her MSc in Health Economics at the University of York. She has since managed a range of health economic and outcomes research projects. Her expertise enables her to conduct both quantitative and qualitative research, including mapping methods for estimation of health state utility, analysis of patient-reported outcomes, patient preference studies and the development and execution of feasibility assessments. She has also supported the building and reviewing of economic models such as cost-effectiveness and budget impact models. India has worked across a variety of disease areas, including rare diseases and epilepsy.

Daniella is involved in a variety of projects at PHMR, including the development of global value dossiers alongside systematic and targeted literature reviews which generate evidence for the purpose of HTA. Daniella has experience in several disease areas, including neurology, renal disease, and oncology. Daniella’s interest in market access across Europe has informed a variety of HTA projects and development of training materials, as well as the PHMR monthly market access alerts which aim to keep clients informed on HTA decisions and key updates in the UK, Germany and France.

Louise has considerable experience in all stages of systematic and targeted literature reviews to inform HTA and has worked on a broad range of projects in multiple disease areas, including oncology, neurology, and renal disease. Louise has a keen interest in value communications and has contributed to the development of several global value dossiers which help our clients demonstrate the value of their products. Louise is also involved in PHMR’s monthly market access alerts which allow clients to keep up to date with HTA decisions. Louise holds a PhD in Nutrition.

Nicola has conducted focussed and pragmatic literature reviews and contributed to projects on clinical trial design and burden of illness studies, global HTA strategies and the use of patient reported outcome measures in HTA. Nicola has extensive experience in clinical trial method development and has developed skills in data extraction and data management, presenting reports in the form of slide decks or word documents, as well the preparation of manuscripts and posters.

Involved in a range of projects, Gabriel has extensive experience of carrying out systematic and pragmatic literature reviews to support submissions to multiple European HTA agencies. He has also contributed to multiple reviews aiming to support the value proposition of technologies in global markets and help clients understand the value of their portfolio of products. Gabriel has worked on global value dossiers to support market access of technologies in Europe, North America and emerging markets, and HTA reviews to understand evidence requirements for approval and reimbursement of combination therapies and highly specialised treatments. Gabriel helped to develop PHMR's Market Access Alerts service and has been published in high-impact journals as well as having presented work at international conferences in the areas of oncology, endocrinology and infectious disease.

Thomas is a statistician and since joining PHMR has been involved in a variety of projects supporting market access through real-world evidence studies and indirect treatment comparisons. In particular, he has conducted several Bayesian network-meta analyses and matching-adjusted indirect comparisons in areas including cardiovascular disease, oncology and neurology. In addition, he has published work in peer-reviewed journals on the development of methodologies and in support of market access and post-market access activities. Thomas has been involved in the development of real-world evidence strategies and is proficient in R, STATA and Python programming languages.

Helen leads the development of value propositions and global value dossiers. She has worked across a wide range of therapeutic areas, including oncology, chronic kidney disease, metabolic disorders, and bladder/bowel health. She is also experienced in conducting systematic literature reviews to support HTA submission and preparing HTA submission dossiers. Helen applies her expert medical writing skills to a broad range of projects at PHMR, including published manuscripts, posters and slide decks.

Aurelie is a health economist with broad experience in economic evaluation, contributing to a variety of projects to support clients' need from development of health economic models for HTA submission purposes to payer tools for engagement with national and local payers. Her expertise also stretches to mapping studies and value frameworks in the cell, gene and rare diseases spaces. Aurelie has broad knowledge of HTA methods and of a variety of statistical software packages.

Anne-Sophie has a wide-ranging experience of health economics and HTA in a range of settings including consultancies, hospitals, pharmaceutical companies and governmental bodies. Such wide-ranging experience has provided her with an in-depth understanding of HTA and reimbursement of pharmaceuticals. Anne-Sophie has developed many HTA submissions for the French HAS (Haute Autorité de Santé) for a range of new therapies including for oncology and orphan designation treatments on behalf of leading pharmaceutical companies. Prior to joining PHMR, Anne-Sophie worked at the Health Products Economics Committee (CEPS) of the French Ministry of Health where she developed valuable insight and experience in pricing processes and negotiations, and evaluation of economic dossiers.

Ally is involved in a variety of projects at PHMR to help clients achieve optimal pricing and reimbursement. She has substantial experience in targeted and systematic literature reviews, research and data interpretation, and communicating complex information in slide decks and scientific reports. Ally has delivered multiple project types including reviews of clinical efficacy, burden of illness and HTA processes, mapping of pricing and reimbursement pathways, treatment landscape analysis, stakeholder interviews, strategic recommendations, value message development, and global value dossiers. She has disease area experience in oncology, infectious disease, chronic kidney disease, chronic inflammatory and autoimmune conditions, muscle wasting, and rare diseases. Ally holds a PhD in cellular biology and tissue engineering from Durham University.

Caroline has been involved in conducting systematic and pragmatic literature reviews of clinical efficacy, economic evaluations, health-related quality of life and burden of illness, to support market access strategies. She has experience in all aspects of the review process, including developing protocols, screening, data extraction and report writing. She has also conducted primary market research with payers and KOLs to assess market access opportunities. Before joining PHMR, Caroline worked in academia in public health research, where she performed observational and interventional studies, as well as systematic and scoping reviews.

Elaine is a medical statistician with extensive experience of statistical input into clinical trials and large public health projects including development of protocols and statistical analysis plans as well as complex data analysis. At PHMR, Elaine's focus has been real-world evidence synthesis and indirect treatment comparisons, working to deliver statistical evidence used to support HTA submissions and inform client decisions around drug efficacy. Elaine is experienced in managing large data sets including patient-level health records and hospital episode statistics and has used these to inform clients on burden of disease and prescribing behaviours. Elaine has published in several peer-reviewed journals and is proficient in the use of advanced statistical software including R, Stata and WinBUGS. Elaine holds an MMathStat from Newcastle University.

Dimitris is a health economist, with broad experience in economic evaluations of therapeutic and diagnostic interventions. He has led and contributed to the conceptualisation and development of cost-effectiveness and budget impact models, in a wide range of software. Dimitris has completed a number of projects for a diverse range of funders and clients including research foundations, pharmaceutical, and medical device companies. He also has conducted systematic literature reviews, and diagnostic meta-analyses, and has broad knowledge of HTA methods and processes. His work covers a wide range of disease areas including oncology, mental health, metabolic diseases, and rare diseases.

Catherine has contributed to a wide range of clinical and economic literature reviews adopting both pragmatic and systematic approaches. She has supported projects across several therapeutic areas, including oncology, epilepsy, and inflammatory bowel disease, applying extensive prior experience from a clinical trial background. Catherine has assisted in the publication of peer-reviewed research on neuroendocrine tumours and holds a PhD in neuroscience from Newcastle University.

Tibi has a part-time role at PHMR. She has expertise in methods for improving health and wellbeing outcomes in workplace settings. Outside of PHMR, Tibi can usually be found networking at nearby Hampstead Heath.